English
Home > Products > CAS:439239-92-6

China CAS:439239-92-6 Manufacturer

We insist over the principle of enhancement of 'High high quality, Efficiency, Sincerity and Down-to-earth working approach' to offer you with superb assistance of processing for CAS:439239-92-6, Top quality, timely company and Aggressive cost, all win us a superior fame in xxx field despite the international intense competition.
CAS:439239-92-6, Our company has a skillful sales team, strong economic foundation, great technical force, advanced equipment, complete testing means, and excellent after-sales services. Our goods have beautiful appearance, fine workmanship and superior quality and win the unanimous approvals of the customers all over the world.

Related Products

Hot Products

  • Estradiol Hemihydrate

    Estradiol Hemihydrate

    Estradiol Hemihydrate has USP and EP specification. DMF available.

    CAS:50-28-2

  • Testosterone

    Testosterone

    Testosterone has CP,EP and USP specifications. CEP, DMF, WC, FDA available..

    CAS:58-22-0

  • Gestodene

    Gestodene

    Gestodene has CP and EP specification. DMF, GMP available.

    CAS:60282-87-3

  • Mometasone Furoate

    Mometasone Furoate

    Mometasone furoate has CP、EP、USP specifications. DMF under filing.

    CAS:83919-23-7

  • 6-chloro-1α-chloromethyl-3,20-dioxo-pregna-4,6-dien-17α-acetoxy

    6-chloro-1α-chloromethyl-3,20-dioxo-pregna-4,6-dien-17α-acetoxy

    6-chloro-1α-chloromethyl-3,20-dioxo-pregna-4,6-dien-17α-acetoxy is the intermediate of Cyproterone acetate.

    CAS:17183-98-1

  • Abiraterone

    Abiraterone

    Abiraterone is a steroidal cytochrome P 450 17α-hydroxylase-17,20-lyase inhibitor (CYP17), It is used in combination with prednisone to treat patients with metastatic castration-resistant prostate cancer (prostate cancer that is resistant to medical or surgical treatments that lower testosterone and has already spread to other parts of the body) and metastatic high-risk castration-sensitive prostate cancer.

    CAS:154229-19-3

  • Related Blog
  • Reviews

  • Gedian Humanwell successfully passed the EDQM audit

    The API -- cyproterone acetate, successfully passed the EU-GMP audit in April 2024.

  • Welcome to Xi'an API 2024

    The 91th API China & PHARMEX & PHARMPACK & SINOPHEX will be held at National Exhibition and Convention Center (Xi’an) from October 16 to 18, our booth number is 3A08.

  • Welcome to CPHI Middle East 2024

    CPHI Middle East 2024 will be held in Riyadh from 10 Dec 2024 - 12 Dec 2024. The pavilion is located at Riyadh Front Exhibition & Convention Center Riyadh and our booth number is 3.G43.

  • Visit us at CPHI Frankfurt - Booth 12.1C3!

    CPHI Frankfurt 2025 will be held at Messe Frankfurt from October 28 to 30, our booth number is 12.1C3.

  • What Is Finasteride and How Does It Work for Hair Loss and Prostate Health

    Finasteride is one of the most widely researched and prescribed medications for treating male pattern hair loss and benign prostatic hyperplasia (BPH). By targeting the hormonal pathways responsible for hair follicle miniaturization and prostate enlargement, Finasteride has become a cornerstone pharmaceutical ingredient in dermatology and urology. This in-depth guide explores how Finasteride works, its benefits, dosage, safety profile, side effects, comparisons with alternatives, and why global pharmaceutical manufacturers such as Humanwell play a crucial role in its production and supply.

  • What Is Dutasteride and How Does It Work to Treat Hair Loss and BPH

    Dutasteride is a powerful 5α-reductase inhibitor widely used in the treatment of benign prostatic hyperplasia (BPH) and increasingly discussed for male pattern hair loss. This article provides a comprehensive overview of what Dutasteride is, how it works at the biochemical level, its benefits, risks, clinical applications, and how it compares with other therapies such as Finasteride.

Send Inquiry

Hit enter to search or ESC to close
X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept